Crispr Therapeutics shares tumble after significant earnings miss
Chief Digital & Technology Officer of Kimberly Clark (NYSE:KMB), Hicks Zackery A, sold 15,038 shares of common stock on August 4, 2025. The sales were executed at prices ranging from $133.38 to $133.48, resulting in a total transaction value of $2,006,117.
Following the transaction, Hicks directly owns 14,321 shares of Kimberly Clark. The company stands out for its impressive 52-year streak of dividend increases, currently offering a 3.86% yield. InvestingPro analysis reveals 8 additional key insights about KMB’s financial position and market outlook, available through their comprehensive research reports.
In other recent news, Kimberly-Clark (NASDAQ:KMB) reported its second-quarter 2025 earnings, which showed an earnings per share (EPS) of $1.92, exceeding the projected $1.65 by 16.36%. Despite this earnings beat, the company faced a revenue shortfall, with $4.16 billion reported against an expected $4.77 billion, marking a 12.79% miss. Goldman Sachs responded to these results by raising its price target for Kimberly-Clark to $145 from $140, maintaining a Buy rating. The firm noted that the company achieved 5% volume-led growth, its strongest in five years, aided by resilient demand and successful innovation initiatives. These developments indicate a mixed but optimistic outlook for the company, as reflected in pre-market trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.